SPARK THERAPEUTICS

Pfizer's hemophilia B gene therapy succeeds in late-stage study

Pfizer's therapy, fidanacogene elaparvovec, is designed to help patients produce factor IX themselves after a one-time treatment, as opposed to current treatments, which focus on regular infusions of the protein.